|
HALL A |
|
08:30-10:00 |
Plenary Session 1
FUTURE THERAPY |
|
|
Diabetes prevention in Asia and worldwide
Metabolic benefits of incremental weight loss
Diagnosis of diabetes by A1C in Asia
Recent trial to prevent CV disease: Is this the Answer or has it created more questions? |
|
10:30-12:30 |
Session 2
FIRST LINE THERAPY FOR T2D AFTER METFORMIN FOCUS ON ASIA |
|
|
Glucosidan INH - First line therapy Vs. metformin
GLP1/DPP4 INH Vs. Sulfonylurea / Insulin / TZDs Pro: Con:
|
|
13:30-15:30 |
Session 3
INSULIN THERAPY IN T2D |
|
Initiation of insulin Not too early: Not too late:
Combinations of Oral Hypoglycemic (OAD) with long-acting analogs
Place of TZD in Asian diabetic patients
|
|
16:00-17:30
|
Session 4
THERAPEUTIC APPROACH TO YOUTH WITH T2DM? IS IT EFFICIENT FOR ASIANS? |
|
Insulin, metformin TZD, glucosidase INH
Combination therapy and lifestyle modifications (based on preliminary results from TODAY study)
|
|
HALL B |
|
10:30-12:30 |
Session 5
|
|
Hypertension as a vascular disease
The endothelium as a target for therapy
Vascular and endothelial function
Vasculature in obesity, diabetes and hypertension
|
|
|
Session 6
TREATMENT GOALS IN DIABETES |
|
Should we aim to normalize A1c? Pro: Con:
The glucotriad: Is glucose variability a cardiovascular (CV) risk factor in its own right? Pro: Con:
|
|
16:00-17:30 |
Session 7
PREVENTION AND TREATMENT OF DIABETIC NEPHROPATHY |
|
Key role of glucose control Pro: Con:
Key role of blood pressure (BP) Control Pro: Con:
Key role of lipid control Pro: Con:
|
|
HALL C |
|
10:30-12:30 |
Session 8
|
|
Cardiometabolic risk assessment and metabolic syndrome controversies
|
|
13:30-15:30 |
Session 9
OPTIMIZING DIABETES THERAPY |
|
Programmed insulin dose calculation Pro: Con:
Benefit of self - monitoring glucose control
Pro: Con:
Continuous glucose monitoring (CGM): For whom will it be beneficial?
|
|
16:00-17:30 |
Session 10 CARDIOVASCULAR RISK IN DIABETES FOCUS ON GENETICS IN ASIA |
|
Hyperglycemia and CVD
Dyslipemia and CVD
Hypertension and CVD
Inflammation and CVD
Cultural obesity
|